Investigational drug · Phase 2
CK0801
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Aplastic Anemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CK0801"
First trial start
2026
Dec 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CK0801", any sponsor or status.
Conditions studied
As listed on its trial records.
- Aplastic Anemia
Approved drugs for the same conditions: Anemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CK0801" as an intervention, largest first.
- A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)Active, not recruiting
Cellenkos, Inc.Industry
NCT03773393 · 18 participants (planned) · Start May 30, 2019 · Primary completion May 25, 2027
Drug: CK0801 · For: Bone Marrow Disease
Sites: Santa Monica, California; Houston, Texas
- CK0801 for Treatment of Aplastic AnemiaNot yet recruiting
Cellenkos, Inc.Industry
NCT07499102 · 12 participants (planned) · Start Dec 3, 2026 · Primary completion Aug 3, 2028
Drug: CK0801 · For: Aplastic Anemia
Cellenkos, Inc.Industry
NCT03773328 · 0 participants · Start Nov 2022 · Primary completion Feb 2025
Drug: CK0801 · For: Guillain-Barré Syndrome
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.
Kadia TM, Huang M, Pemmaraju N, et al. · NEJM Evid 2024
Also in development for Aplastic Anemia
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.